Obesity Science & Practice最新文献

{"title":"Preventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial.","authors":"Kelseanna Hollis-Hansen, Alexander Vonderschmidt, Carolyn Haskins, Ryan M Kane, Jaime P Almandoz, Ildiko Lingvay","doi":"10.1002/osp4.70194","DOIUrl":"10.1002/osp4.70194","url":null,"abstract":"<p><strong>Objective: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference, and other factors. Weight regain often occurs rapidly after cessation, yet few evidence-based strategies exist to support weight maintenance during this transition. This pilot randomized trial examined whether a digital wellness application or medically tailored meals (MTM) could mitigate weight gain during the first 4 months after GLP-1 cessation.</p><p><strong>Methods: </strong>In this pilot randomized trial, adults with prior GLP-1-induced weight loss were randomized to usual care, wellness application, or MTM at the time of GLP-1 cessation. Surveys assessed adherence and satisfaction (primary outcome) as well as exploratory outcomes, diet quality, and perceived health. Weight (exploratory) was measured monthly using validated Bluetooth scales.</p><p><strong>Results: </strong>Participants (<i>n</i> = 39) were randomized to control (<i>N</i> = 14), digital wellness application (<i>N</i> = 12), or MTM (<i>N</i> = 13) and had a mean baseline BMI 31.4 (SD 6.3) kg/m². Diet quality, perceived health, adherence, and satisfaction did not significantly differ by group, though some estimates suggested possible trends favoring the wellness application. Relative to control, both the wellness application and MTM groups had less total weight gain: Wellness application -7.16% (95% CI: -12.27, -2.04) and MTM -7.17% (-12.20, -2.14).</p><p><strong>Conclusions: </strong>These findings suggest that structured support may attenuate early weight gain after GLP-1 cessation. Larger, more diverse trials with longer follow-up and clinical outcomes are needed to confirm results and clarify mechanisms.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 5","pages":"e70194"},"PeriodicalIF":2.5,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13643368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Knowledge of GLP-1 Receptor Agonists for Obesity and Exploration of Potential Household-Level Effects in an Urban Health System.","authors":"Leah M Schumacher, Elise Rodrigues, Erin Mraz, Doria Wohler, Astha Rajpal, Sharon J Herring, Daniel J Rubin, Ajay D Rao, Laura Igarabuza, Samantha Flanagan, Daniel Edmundowicz, Resa M Jones","doi":"10.1002/osp4.70199","DOIUrl":"10.1002/osp4.70199","url":null,"abstract":"<p><strong>Background: </strong>The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity management has gained widespread popularity and media attention. However, little is known about patients' knowledge related to GLP-1 RAs (e.g., prescribing indications, side effects), how patients currently learn and wish to learn about GLP-1 RAs, and how GLP-1 RA use may impact weight-related behaviors and attitudes within households (e.g., food purchasing patterns).</p><p><strong>Objective: </strong>This study evaluated these questions among diverse adults recruited from a large, urban health system.</p><p><strong>Methods: </strong>Participants were recruited to complete a brief online questionnaire through flyers posted in several outpatient clinics within a large health system. Recruitment occurred from November 2024 to April 2025. Descriptive statistics were calculated.</p><p><strong>Results: </strong>Fifty-two patients completed the questionnaire. Overall, 98% of participants had heard at least \"a little\" about GLP-1 RAs. The conditions participants most commonly believed could benefit from use were obesity (88%), diabetes (75%), and high blood pressure (43%). The side effects they had heard most about were nausea/vomiting (71%), diarrhea (49%), and constipation (47%). Expected amount of weight loss and understanding of GLP-1 RAs' mechanisms of action varied widely. The most common GLP-1 RA information source was commercials/advertisements (73%); however, the most frequently preferred information source was healthcare professionals (87%). In exploratory analyses among patients with current or past GLP-1 RA use and ≥ 1 other household member (<i>n</i> = 12), 75% believed their use impacted adult household members' attention to weight, eating, or exercise; 50% believed GLP-1 RA use impacted child/adolescents household members' attention to these matters; and 42% reported perceived weight loss among household adult(s). All GLP-1 RA users reported changes in their household meal behaviors, and many reported shifts toward more healthful food purchases.</p><p><strong>Conclusion: </strong>These findings suggest that many patients understand the primary indications for GLP-1 RAs for obesity and common side effects, while also highlighting opportunities for improved decision support. Additional research on a potential \"ripple effect\" within households using larger samples and more robust methods is warranted.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 5","pages":"e70199"},"PeriodicalIF":2.5,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triglyceride-Glucose-Waist Circumference Index as a Surrogate Marker for Visceral Obesity: Analysis of NHANES 2011-2018.","authors":"Pan Fu, Yue Li, Keqin Zhang","doi":"10.1002/osp4.70163","DOIUrl":"10.1002/osp4.70163","url":null,"abstract":"","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 4","pages":"e70163"},"PeriodicalIF":2.5,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13505882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes and Predictors of Success for Very Low Calorie Diets in an Australian Publicly Funded Bariatric Medicine Service.","authors":"Rebecca Mathews, Alice Richardson, Eloise Brewer, Louise Brightman, Hsin-Chia Carol Huang","doi":"10.1002/osp4.70186","DOIUrl":"10.1002/osp4.70186","url":null,"abstract":"<p><strong>Objective: </strong>Enablers of successful completion and outcomes from Very Low Calorie Diets (VLCD) conducted in real-life clinical settings are poorly understood. This study explored weight and metabolic changes following VLCD and identified baseline factors associated with VLCD completion, weight-loss, and weight-loss maintenance.</p><p><strong>Methods: </strong>A retrospective chart review was conducted for patients beginning VLCD between February 1, 2018 and October 31, 2020 at an Australian bariatric medicine service. Univariate analyses assessed weight, glycemic control, blood pressure, and cholesterol changes following 6 and 12 weeks of VLCD. Multivariate analyses explored factors predicting clinically significant weight-loss (CWL), VLCD completion and weight-loss maintenance.</p><p><strong>Results: </strong>The 90 patients who completed VLCD had statistically significant improvements in mean weight and percentage weight lost, blood pressure, glycemic and cholesterol control at 6 (all <i>p</i> < 0.0001) and 12 weeks (all <i>p</i> < 0.0001). Obstructive sleep apnea (OSA) and depression symptoms were negative predictors of CWL (all <i>p</i> < 0.05). Weight lost by week 6 positively predicted VLCD completion (<i>p</i> = 0.01); weight-promoting medications negatively predicted this (<i>p</i> = 0.02).</p><p><strong>Conclusions: </strong>Weight promoting medications may hinder VLCD completion. OSA and depression have the potential to impede weight-loss from VLCD. Addressing these factors before starting VLCD may enable better adherence and outcomes.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 4","pages":"e70186"},"PeriodicalIF":2.5,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13501394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity Severity and Burden of Illness: Perceptions From Physicians and People With Obesity in the UK.","authors":"Lill-Brith Von Arx, Andrea Leith, Lewis Harrison, Tamara Mensah, Simon Coates, Esther Artime, Katrien Wijndaele, Giles S H Yeo","doi":"10.1002/osp4.70185","DOIUrl":"https://doi.org/10.1002/osp4.70185","url":null,"abstract":"<p><strong>Background: </strong>Despite the availability of various obesity treatment options, unmet needs in obesity management remain an obstacle to optimal weight management and result in negative impacts on people with obesity (PwO). To improve obesity management, it is important to understand the disease burden experienced by PwO, and the perceptions of obesity held by both PwO and physicians.</p><p><strong>Objective: </strong>To describe the characteristics of PwO, the illness burden and management of obesity and the perceptions of obesity from consulting PwO and their physicians in the United Kingdom.</p><p><strong>Methods: </strong>Data were collected from the Adelphi Real World Obesity Disease Specific Program (DSP) between 10/2023 and 04/2024. PwO were adults on a weight management program with a previous or current obesity diagnosis. Physicians and PwO completed surveys of PwO sociodemographic and clinical characteristics, healthcare resource utilization, work-related activity and productivity impairment, perceptions on the etiology of obesity and PwO's feelings toward weight.</p><p><strong>Results: </strong>Ninety-four physicians completed surveys on 904 PwO, and 119 of those PwO also completed a survey. Most (88.3%) PwO had ≥ 1 obesity-related complication (ORC). The most common management approaches were diet and exercise. Physician-stated reasons for obesity were diet and behavioral factors, while PwO-stated reasons included aging and genetic predisposition for obesity. PwO reported a work productivity impact due to obesity, and 42.9% reported feeling very bothered about their weight.</p><p><strong>Conclusions: </strong>Most PwO in the DSP had ≥ 1 ORC. PwO reported negative work-related and emotional impacts due to obesity. Differences in the physician- and PwO-stated reasons for obesity demonstrate misconceptions around obesity etiology.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 4","pages":"e70185"},"PeriodicalIF":2.5,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13488004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Remote Program for Navigator- and Pharmacist-Led Management of Obesity Medications in Adults: Rationale, Design, and Implementation.","authors":"Bryn Falahee, John W Ostrominski, Kavishwar B Wagholikar, Ozan Unlu, David Zelle, Sanjay Kumar, Daniel Gabovitch, Michela Tucci, Austen Smith, Hunter Nichols, Irene G McCarthy, Samar Mushtaque, Tabitha V Rutkowski, Ashley C McCarthy, Heather J Baer, Christopher P Cannon, Naomi D L Fisher, Jorge Plutzky, Caroline M Apovian, Benjamin M Scirica, Alexander J Blood","doi":"10.1002/osp4.70176","DOIUrl":"https://doi.org/10.1002/osp4.70176","url":null,"abstract":"<p><strong>Objective: </strong>Remote interventions leveraging team-based care may ameliorate persistent gaps in obesity medication implementation, but prospective studies are lacking. In this paper, the design, enrollment, and implementation of a remote intervention for obesity medications are described.</p><p><strong>Methods: </strong>The Supplementary Anti-Obesity Medication Integration into a Longitudinal Obesity (SAIL) study is a fully remote program with pharmacist- and navigator-led obesity medication implementation. Individuals with body mass index (BMI)-defined overweight or obesity receiving a digital lifestyle intervention were recruited for participation in SAIL via a survey. Effectiveness outcomes included obesity medication prescription and body weight change at 6 months. Focus groups were conducted with study staff after program completion to identify implementation barriers and solutions.</p><p><strong>Results: </strong>Between June 2023 and September 2024, 200 patients responded to the survey, of which 99 were eligible. Of these, 75 enrolled in SAIL (mean age, 50 ± 12 years; 83% women; mean BMI 36 ± 6 kg/m²). Focus groups identified multiple implementation challenges and opportunities, including medication access, insurance coverage, and patient education. Addressing misinformation, frequent patient engagement, and program flexibility emerged as unique strengths of SAIL.</p><p><strong>Conclusions: </strong>The final results of SAIL will inform the effectiveness of remote, algorithm-driven, navigator- and pharmacist-led programs for obesity medication prescription and management.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 4","pages":"e70176"},"PeriodicalIF":2.5,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13476458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148762135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Partner Weight Loss and Diet Outcomes at 24 Months in a Randomized Controlled Trial of a Dyadic Versus Individual Weight Management Intervention.","authors":"Kristen E Gray, Laura S Porter, Ryan J Shaw, Kara L Gavin, Scott J Hetzel, Megan A Lewis, Samantha Pabich, Heather M Johnson, Felix Elwert, Lu Mao, Katya Garza, William S Yancy, Corrine I Voils","doi":"10.1002/osp4.70178","DOIUrl":"10.1002/osp4.70178","url":null,"abstract":"<p><strong>Background: </strong>Including romantic partners as supports in behavioral weight management programs targeting index participants could yield spillover effects, but few studies have explored the effects on partners.</p><p><strong>Methods: </strong>Dyads included an index participant with BMI ≥ 27 kg/m² and a cohabitating partner with BMI ≥ 18 kg/m² randomized to a participant-only (<i>N</i> = 116) or partner-assisted (<i>N</i> = 115) intervention. All index participants received an evidence-based group weight management program. Partners in the partner-assisted group attended half of the sessions but were not required to make behavioral changes/lose weight. Linear mixed models compared changes in partner weight and self-reported caloric intake between groups at 24 months.</p><p><strong>Results: </strong>Most partners identified as male (63%) and White (88%). Mean baseline weight and BMI were 98 kg (SD 28.1) and 32 kg/m² (SD 7.8), respectively. At 24 months, partners in the partner-assisted versus participant-only group lost more weight (-2.5 kg vs. -0.4 kg; estimated mean difference: -2.0 kg [95% CI -3.5, -0.6]). There were no differences in caloric change (partner-assisted: -367 kcal, participant-only: -196 kcal; estimated mean difference: -171 kcal [95% CI -358, 17]).</p><p><strong>Conclusions: </strong>Involving romantic partners is an efficient weight management approach that generates meaningful long-term weight loss for cohabitating partners despite them not being the direct targets for weight loss.</p><p><strong>Trial registration: </strong>Clinicaltrials.gov NCT03801174.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 4","pages":"e70178"},"PeriodicalIF":2.5,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13463752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148726893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Pragmatic Outpatient Framework for Appetite-Related Phenotyping in Obesity.","authors":"Jassel Arturo Velázquez-Navarro, Roberto Rodríguez-Moriel, Roxana Michel Márquez-Herrera, Luis Antonio Ramos-Márquez","doi":"10.1002/osp4.70184","DOIUrl":"10.1002/osp4.70184","url":null,"abstract":"<p><strong>Background: </strong>Previous obesity phenotyping models have been proposed; however, current protocols rely on complex physiological assessments that are difficult to implement in routine outpatient care.</p><p><strong>Aim: </strong>To describe and apply a pragmatic outpatient framework for appetite-related phenotyping integrating standardized satiety testing and emotional eating assessment.</p><p><strong>Methods: </strong>In this observational study, adults with overweight or obesity underwent a standardized mixed-meal satiety test using visual analogue scales together with emotional eating assessment using the Emotional Eating Questionnaire. Exploratory thresholds were derived from a normal-weight reference group. Participants were classified into appetite-related phenotypes: impaired early satiety, impaired late satiety, emotional eating, overlap, and no dominant phenotype.</p><p><strong>Results: </strong>A total of 129 adults with overweight or obesity were included. Impaired early satiety was identified in 48.1% of participants, impaired late satiety in 35.7%, and normal satiety responses in 16.3%. Severe emotional eating was present in 12.4% of participants. Overlap between emotional eating and altered satiety-test responses was identified in 11% of participants.</p><p><strong>Conclusions: </strong>Most participants exhibited at least one appetite-related phenotype, supporting the relevance of assessing both homeostatic (satiety) and emotional dimensions of eating behavior in clinical practice. Future studies should evaluate reproducibility and potential implications for phenotype-guided obesity treatment.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 4","pages":"e70184"},"PeriodicalIF":2.5,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13449295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.","authors":"A B M Kamrul-Hasan, Hamid Ashraf, Lakshmi Nagendra, Ibrahim Khalil, Subhankar Chatterjee, Deep Dutta, Tahniyah Haq, Mansuor A Alanazi, Joseph M Pappachan","doi":"10.1002/osp4.70181","DOIUrl":"10.1002/osp4.70181","url":null,"abstract":"<p><strong>Background: </strong>Oral GLP-1 receptor agonists (GLP-1 RAs) offer a non-injectable option for weight management in adults with overweight/obesity without diabetes. This network meta-analysis (NMA) evaluated their effects on body weight.</p><p><strong>Methods: </strong>A frequentist random-effects NMA of RCTs comparing oral GLP-1 RAs with placebo in adults without diabetes was conducted by searching databases through 30 April 2026. The primary outcome was percent change in body weight, with secondary outcomes including other weight measures and weight thresholds. Analyses used R (netmeta), and certainty was assessed with CINeMA.</p><p><strong>Results: </strong>Nine RCTs (<i>N</i> = 5766; 20-72 weeks) evaluating oral semaglutide, orforglipron, danuglipron, and lotiglipron were included. All agents except low-dose (LoD) lotiglipron outperformed placebo in percent body weight reduction; high-dose (HiD) semaglutide (MD -11.6%) and orforglipron (MD -11.8%) showed the greatest effects. Orforglipron HiD produced the greatest absolute weight loss (MD -12.2 kg), whereas semaglutide HiD reduced BMI (MD -4.7 kg/m²) and waist circumference (MD -10.0 cm) the most. Danuglipron HiD, semaglutide HiD, and semaglutide LoD ranked highest for ≥ 5%, ≥ 10%, and ≥ 15% weight loss, respectively. Evidence certainty was low to moderate.</p><p><strong>Conclusion: </strong>HiD oral semaglutide and orforglipron demonstrated the most consistent and substantial weight reductions though low-to-moderate certainty and lack of head-to-head comparisons constrain comparative inference.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 4","pages":"e70181"},"PeriodicalIF":2.5,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13445785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148685393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UK Healthcare Professionals' Knowledge, Attitudes, and Beliefs About Adult Obesity: A Qualitative Study.","authors":"Paul MacDonald, Helen Frank, Rebecca Stack","doi":"10.1002/osp4.70182","DOIUrl":"10.1002/osp4.70182","url":null,"abstract":"<p><strong>Background: </strong>Healthcare professionals' knowledge, attitudes, and beliefs toward adults living with obesity influence clinical engagement, communication, and quality of care. However, existing outcome measurement instruments used to assess these constructs have demonstrated limitations in development quality, contextual relevance, and content validity, particularly within the United Kingdom (UK) healthcare system.</p><p><strong>Objective: </strong>To conduct a qualitative concept elicitation study aligned with the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) recommendations to identify key themes shaping UK healthcare professionals' knowledge, attitudes, and beliefs regarding adults living with obesity in order to inform the development of an outcome measurement instrument.</p><p><strong>Design: </strong>Qualitative descriptive study using semi-structured group and individual interviews.</p><p><strong>Methods: </strong>35 UK healthcare professionals from multiple disciplines participated in semi-structured individual and group interviews. Data were analysed using inductive reflexive thematic analysis in accordance with COSMIN recommendations for content validity and item generation.</p><p><strong>Results: </strong>Four interrelated themes were identified: (1) clinical working environment, (2) knowledge of obesity, (3) attitudes to obesity, and (4) beliefs about professional roles. The clinical working environment was identified as a primary contextual determinant influencing how knowledge is constructed, how attitudes are expressed, and how beliefs about professional roles are enacted in practice. Structural constraints, organizational culture, role ambiguity, and service limitations influenced clinicians' confidence, communication, and perceived legitimacy in adult obesity care.</p><p><strong>Conclusion: </strong>Healthcare professionals' knowledge, attitudes, and beliefs regarding adult obesity are not solely individual attributes but are embedded within organizational and service contexts. These findings provide a strong empirical foundation for COSMIN-aligned item development and support the creation of a context-sensitive outcome measurement instrument to inform research, workforce development, and service improvement in UK adult obesity care.</p><p><strong>Patient or public contribution: </strong>Patient and Public Involvement (PPI) contributors reviewed the interview guide to ensure clarity and relevance prior to data collection.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 4","pages":"e70182"},"PeriodicalIF":2.5,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13435368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148674157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}